These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 18695321)

  • 1. Incidence of carbapenem-resistant Pseudomonas aeruginosa in diabetes and cancer patients.
    Varaiya A; Kulkarni M; Bhalekar P; Dogra J
    Indian J Med Microbiol; 2008; 26(3):238-40. PubMed ID: 18695321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in diabetes and cancer patients.
    Varaiya A; Kulkarni M; Bhalekar P; Dogra J
    Indian J Pathol Microbiol; 2008; 51(2):200-3. PubMed ID: 18603681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpreting carbapenem susceptibility testing results for Pseudomonas aeruginosa.
    Micaëlo M; Brossier F; Bréchot N; Luyt CE; Lu Q; Monsel A; Jarlier V; Aubry A
    Med Mal Infect; 2018 Aug; 48(5):365-371. PubMed ID: 29628176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
    Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
    Castanheira M; Deshpande LM; Costello A; Davies TA; Jones RN
    J Antimicrob Chemother; 2014 Jul; 69(7):1804-14. PubMed ID: 24603963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem nonsusceptibility with modified
    Choudhury D; Talukdar AD; Choudhury MD; Maurya AP; Chanda DD; Chakravorty A; Bhattacharjee A
    Indian J Med Microbiol; 2017; 35(1):137-139. PubMed ID: 28303836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
    Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
    J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
    Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
    Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of carbapenem-hydrolysing metallo-beta-lactamase VIM-1 in Pseudomonas aeruginosa isolates in France.
    Corvec S; Poirel L; Decousser JW; Allouch PY; Drugeon H; Nordmann P
    Clin Microbiol Infect; 2006 Sep; 12(9):941-2. PubMed ID: 16882306
    [No Abstract]   [Full Text] [Related]  

  • 16. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients.
    Varaiya A; Kulkarni N; Kulkarni M; Bhalekar P; Dogra J
    Indian J Med Res; 2008 Apr; 127(4):398-402. PubMed ID: 18577797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals.
    Wang J; Zhou JY; Qu TT; Shen P; Wei ZQ; Yu YS; Li LJ
    Int J Antimicrob Agents; 2010 May; 35(5):486-91. PubMed ID: 20185276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
    Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.